FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
The enzyme mTOR (mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein. Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN (phosphatase and tensin homolog), which also activates mTOR. Tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, which suggests that loss of FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.
Mao
Jian-Hua
JH
Cancer Research Institute, University of California at San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Kim
Il-Jin
IJ
Wu
Di
D
Climent
Joan
J
Kang
Hio Chung
HC
DelRosario
Reyno
R
Balmain
Allan
A
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism*; D002460:Cell Line; D045744:Cell Line, Tumor; D044783:F-Box Proteins / Q000235:genetics / Q000378:metabolism*; D000073979:F-Box-WD Repeat-Containing Protein 7; D017353:Gene Deletion; D018628:Gene Dosage; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009154:Mutation; D009368:Neoplasm Transplantation; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D011485:Protein Binding; D011494:Protein Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014162:Transfection; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000378:metabolism*; D054875:Ubiquitination
D018797:Cell Cycle Proteins; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D011494:Protein Kinases; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D020123:Sirolimus
Mol Cell Biol. 2001 Nov;21(21):7403-15
11585921
Cancer Res. 2007 Jan 15;67(2):818-26
17234794
Cancer Res. 2005 Dec 15;65(24):11361-6
16357143
BMC Cancer. 2006 Apr 18;6:96
16620391
EMBO J. 2004 May 19;23(10):2116-25
15103331
Oncogene. 2003 Nov 20;22(52):8379-85
14627978
Oncogene. 2008 Jul 3;27(29):4086-95
18332865
Cancer Cell. 2006 Dec;10(6):515-27
17157791
Cancer Cell. 2006 Dec;10(6):529-41
17157792
Curr Biol. 2004 Oct 26;14(20):1852-7
15498494
Nature. 2001 Sep 20;413(6853):316-22
11565034
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
15150404
Curr Cancer Drug Targets. 2005 Feb;5(1):57-68
15720190
Nat Genet. 1998 Aug;19(4):348-55
9697695
Nature. 2004 Mar 4;428(6978):77-81
14999283
Cancer Res. 2007 Oct 1;67(19):9006-12
17909001
Nature. 2004 Dec 9;432(7018):775-9
15592418
Nat Rev Cancer. 2008 Feb;8(2):83-93
18094723